Select Page ::

Genome-wide association study of cardiovascular disease in testicular cancer patients treated with platinum-based chemotherapy. – UroToday

Posted on October 10, 2020 by Danzig

Genetic variation may mediate the increased risk of cardiovascular disease (CVD) in chemotherapy-treated testicular cancer (TC) patients compared to the general population. Involved single nucleotide polymorphisms (SNPs) might differ from known CVD-associated SNPs in the general population. We performed an explorative genome-wide association study (GWAS) in TC patients. TC patients treated with platinum-based chemotherapy between 1977 and 2011, age 55 years at diagnosis, and 3 years relapse-free follow-up were genotyped. Association between SNPs and CVD occurrence during treatment or follow-up was analyzed. Data-driven Expression Prioritized Integration for Complex Trait (DEPICT) provided insight into enriched gene sets, i.e., biological themes. During a median follow-up of 11 years (range 3-37), CVD occurred in 53 (14%) of 375 genotyped patients. Based on 179 SNPs associated at p0.001, 141 independent genomic loci associated with CVD occurrence. Subsequent, DEPICT found ten biological themes, with the RAC2/RAC3 network (linked to endothelial activation) as the most prominent theme. Biology of this network was illustrated in a TC cohort (n=60) by increased circulating endothelial cells during chemotherapy. In conclusion, the ten observed biological themes highlight possible pathways involved in CVD in chemotherapy-treated TC patients. Insight in the genetic susceptibility to CVD in TC patients can aid future intervention strategies.

The pharmacogenomics journal. 2020 Oct 03 [Epub ahead of print]

Lars C Steggink, Hink Boer, Coby Meijer, Joop D Lefrandt, Leon W M M Terstappen, Rudolf S N Fehrmann, Jourik A Gietema

Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, Hanzeplein 1, 9713 GZ, Groningen, The Netherlands., Department of Internal Medicine, Division of Vascular Medicine, University Medical Center Groningen, University of Groningen, Groningen, Hanzeplein 1, 9713 GZ, Groningen, The Netherlands., Medical Cell BioPhysics, University of Twente, Drienerlolaan 5, 7522 NB, Enschede, The Netherlands., Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, Hanzeplein 1, 9713 GZ, Groningen, The Netherlands. .

PubMed http://www.ncbi.nlm.nih.gov/pubmed/33011741

Read the rest here:
Genome-wide association study of cardiovascular disease in testicular cancer patients treated with platinum-based chemotherapy. - UroToday

Veterinary Therapeutics Market 2020 Analysis & Forecast to 2026 by Key Players, – News.MarketSizeForecasters.com

Posted on September 23, 2020 by Danzig

Market Study Report, LLC, has added a detailed study on the Veterinary Therapeutics market which provides a brief summary of the growth trends influencing the market. The report also includes significant insights pertaining to the profitability graph, market share, regional proliferation and SWOT analysis of this business vertical. The report further illustrates the status of key players in the competitive setting of the Veterinary Therapeutics market, while expanding on their corporate strategies and product offerings.

The latest research report on the Veterinary Therapeutics market assesses the major factors influencing industry growth with respect to the competitive dynamics and geographical reach. It also ensembles the challenges prevalent in this industry vertical and identifies opportunities that will further aid business expansion. Further, the report revisits all areas of the business to cover the impact of COVID-19 pandemic so as to assist stakeholders in devising new strategies and reinforcing their position in the market.

Request a sample Report of Veterinary Therapeutics Market at:https://www.marketstudyreport.com/request-a-sample/2908669?utm_source=msf&utm_medium=RV

Key pointers from COVID-19 impact analysis:

Important inclusions in the Veterinary Therapeutics market report:

Ask for Discount on Veterinary Therapeutics Market Report at:https://www.marketstudyreport.com/check-for-discount/2908669?utm_source=msf&utm_medium=RV

Regional scope:

TOC of Veterinary Therapeutics Market Report Includes:

The Report Answers the key Questions

For More Details On this Report: https://www.marketstudyreport.com/reports/global-veterinary-therapeutics-market-report-2020-by-key-players-types-applications-countries-market-size-forecast-to-2026-based-on-2020-covid-19-worldwide-spread

Related Reports:

1. Global HIV Therapeutics Market Report 2020 by Key Players, Types, Applications, Countries, Market Size, Forecast to 2026 (Based on 2020 COVID-19 Worldwide Spread)Read More: https://www.marketstudyreport.com/reports/global-hiv-therapeutics-market-report-2020-by-key-players-types-applications-countries-market-size-forecast-to-2026-based-on-2020-covid-19-worldwide-spread

2. Global Pharmacogenomics (PGX) Market Report 2020 by Key Players, Types, Applications, Countries, Market Size, Forecast to 2026 (Based on 2020 COVID-19 Worldwide Spread)Read More: https://www.marketstudyreport.com/reports/global-pharmacogenomics-pgx-market-report-2020-by-key-players-types-applications-countries-market-size-forecast-to-2026-based-on-2020-covid-19-worldwide-spread

Why Well Health (TSX:WELL) Is the Stock to Buy as the 2nd COVID-19 Wave Hits – The Motley Fool Canada

Posted on September 23, 2020 by Danzig

As the second wave of the coronavirus hits, Well Health Technologies(TSX:WELL) stock is seeing rapid growth. Technology has always been underappreciated and underutilized in primary care healthcare. But today, the coronavirus has brought its merits to light like never before. We now know two things for sure.

Firstly, today in this pandemic, we need technology in primary healthcare like never before. It is allowing us to access our doctors while maintaining distancing. Secondly, the benefits of technology in primary healthcare are multi-faceted. Technology will continue to transform and improve healthcare for the long haul.

Here are the reasons why WELL stockis a stock to buy.

Well Healths stock price has shot up in 2020. This is no surprise, as demand for telemedicine has skyrocketed in the pandemic. Well Healths revenue in the first six months of 2020 increased 40%. In 2019, Well Healths revenue increased 211%.

With a $938 million market capitalization and a rapidly growing healthcare asset base, Well Health continues to transform the primary healthcare industry. The company continues to acquire clinical and digital healthcare assets.

As the second wave hits, Well Healths clinics and services will be even more in demand. And the benefits of telemedicine will become more and more obvious. With this, Well Health stock will continue its rise.

Well Health has a fast-growing digital portfolio of healthcare assets. It has 2,000 clinics, over 10,000 supported general practitioners, and over 15 million registered patients. The companys clinic portfolio is also becoming more and more sizable. It has 19 wholly-owned clinics and approximately 180 doctors at these clinics.

The primary healthcare system is one of the last big industries that has yet to digitize. According to Well Health reports, the Canadian primary care industry is a $250 billion industry. Physician spending accounts for approximately 15.4%. The industry is plagued by underinvestment, fragmentation and a lack of technology.

Well Health aims to change this. The benefits are big and they are clear. Digital tools can increase operational efficiency. They can improve patient care. They can allow physicians to focus more on what matters.

Virtual care ensures easy access to doctors. This has been key in the coronavirus pandemic. It will be even more key as the second wave hits. Waiting room automation allows for shorter wait times for patients. These are examples of what technology can do. But there are also more significant advantages.

Precision medicine proposes customizing healthcare decisions, treatments, practices, and products to suit individual patient needs. It basically means identifying best approaches tailored for a specific patient. Genetic, environmental, and lifestyle factors all play a role in determining a patients treatment. We can easily see how a digital database of information on each patient is key for this purpose.

In the future, a digital database with patients DNA can take all this a step further. Pharmacogenomics is the study of how genes affect a persons response to particular drugs. A database that has genetic data, biological samples, and other health information will step up healthcare into a new age.

Well Health stock has so much going for it. It has a significant runway of growth ahead as it participates in the digitization of the healthcare system. Patient care is improving and primary care offices are becoming more efficient. WELL stock trades at just over $6.50 at the time of writing. It has risen 130% in the last three months. Expect more big increases in the short, medium, and long term.

Fool contributor Karen Thomas has no position in any of the stocks mentioned.

Visit link:
Why Well Health (TSX:WELL) Is the Stock to Buy as the 2nd COVID-19 Wave Hits - The Motley Fool Canada

Innovative Gx Laboratories Announces the Grand Opening of Its Molecular Diagnostic Laboratory in Texas – Yahoo Finance

Posted on October 4, 2020 by Danzig

InvestorPlace

With so much death and economic destruction wrought by the novel coronavirus, its hard to find the silver lining. But if there is one on Wall Street, its the rise of artificial intelligence stocks. Yes, there is the profitability angle from machine learning and other relevant technology facilitates. But this crisis has been a crash course in the sectors viability.Hopefully, we wont suffer a second wave like many European countries are experiencing because, you know, people can just get over themselves and wear a flipping mask in public. But even if we do succumb to a second round, eventually, this too shall pass. However, the return to some sense of normalcy will likely take time. Thus, we may depend on contactless platforms. Of course, this international emergency has provided an excellent arena for finetuning.As well, its becoming clear that the scale and acceleration of our globalized economy is more than human brains can handle. Yes, we are the ultimate innovative species (as far as I know). However, machines can now play a major role in alleviating most if not one day all of our menial tasks. That frees us up for greater and more meaningful innovations, which is the underlying ethos of artificial intelligence stocks.InvestorPlace - Stock Market News, Stock Advice & Trading TipsThis isnt just techno-babble gibberish. For instance, the food supply chain was put under enormous stress during the peak of Covid-19. Well before the pandemic, many retailers partnered with AI programmers to develop enhanced forecasting and planning infrastructure. Now, this need has accelerated due to the baptism of fire. Therefore, these diverse artificial intelligence stocks could enjoy upside throughout this year and beyond.Apple (NASDAQ:AAPL)Alphabet (NASDAQ:GOOG, NASDAQ:GOOGL)IBM (NYSE:IBM)Nvidia (NASDAQ:NVDA)Tencent (OTCMKTS:TCEHY)Match Group (NASDAQ:MTCH)Trade Desk (NASDAQ:TTD)The 7 Top Robinhood Stocks for OctoberFinally, not everything about AI has to be so serious. Since were conducting our business and personal affairs increasingly online, almost anything that we can think of, including love and dating, can benefit from the integration of man and machine. Since this dynamic is well under way, here are the seven artificial intelligence stocks from which you can profit.Apple (AAPL)Source: View Apart / Shutterstock.comAs the manufacturer of the now-iconic iPhone, Apple is more well known as a consumer electronics behemoth rather than an investment into artificial intelligence stocks. Certainly, the company can bank simply on the power of its globally recognized brand. However, what makes AAPL stock special is that management refuses to be satisfied with its prior accomplishments.As evidence, consider Apples foray into electric vehicles. At one point, rumors circulated that hundreds of people were developing a car, one that could possibly compete with Tesla (NASDAQ:TSLA). Nowadays, it appears that the consumer tech firm is focusing on developing software for self-driving cars. If thats the case, such a course would require significant innovations in AI, particularly machine learning.Theoretically, Apple has a lot of practice in this arena thanks to its wealth of consumer data. In addition, the company has forged consumer friendly applications, such as palm rejection technology. This nifty development allows the iPad to recognize the difference between a deliberate input with the Apple Pencil versus accidental contact with a part of the hand.Undoubtedly, most investors will buy AAPL stock for its ever-popular smart devices. However, those who are interested in artificial intelligence stocks should also give it serious consideration.Alphabet (GOOG, GOOGL)Source: BigTunaOnline / Shutterstock.comWhenever anyone talks about artificial intelligence stocks, Alphabet is one of the top names thats mentioned and for good reason. Essentially, Alphabets Google owns the internet. As of July 2020, Google dominated desktop search engines with an 87% global market share. With figures like that, youre bound to have a wealth of consumer data that other organizations can only dream about.And with search dominance comes its web advertisement-driven revenue channels. Corporations spend billions buying up Google ads because thats where the people are. In turn, Alphabet has gotten quite adept at utilizing its AI infrastructure to fine-tune what consumers want and just as importantly, when they want it. Additionally, thanks to its YouTube platform, Alphabet has years of valuable experience understanding and predicting consumer behavior.Therefore, while GOOGL stock is often the target of social and political criticism, I dont see the internet giant going anywhere but up over a long-term horizon.7 Internet of Things Stocks for Investing in InnovationPlus, what really makes Alphabet stand out is its penchant for relevant acquisitions. For example, its DeepMind subsidiary specializes in traffic prediction algorithms. Thats not just important for everyday convenience but also as a framework for smart city infrastructures. Therefore, if you want more AI in your portfolio, go get some GOOGL stock.IBM (IBM)Source: JHVEPhoto / Shutterstock.comAlthough artificial intelligence stocks represent one of the hottest segments on Wall Street, individual names tend to be well-known entities. As such, theyre not exactly what you would call undervalued as they typically have already garnered much investor sentiment.Well, IBM doesnt have that problem. As a legacy tech giant, Big Blue has struggled over the years to shed its image of yesteryear innovations. Instead, management has pivoted to many relevant markets, including cloud computing and cybersecurity. However, IBM stock is frustrating, even in this year where its down 10% while other tech firms are up big.Nevertheless, if you want to go against the grain with your artificial intelligence stocks, IBM offers the patient investor potentially significant upside. As you know, with its AI platform Watson, Big Blue has been helping multiple enterprises and industries maximize their efficiency. One particular area that Im intrigued in is healthcare.With the novel coronavirus having disrupted this sector, theres never been a more critical time for improved efficiencies. Here, IBM could make a conspicuously positive impact, reducing administrative friction so that medical professionals can spend less time on paperwork and more time helping patients. Having learned tough lessons from the new normal, the pandemic could help IBM stock regain its footing.Nvidia (NVDA)Source: Hairem / Shutterstock.comWhen you hear the brand Nvidia, most likely what comes to mind first is video games. And thats not a bad thing, believe me. Before the pandemic, video games, especially the rise of eSports, helped drive the bullish case for NVDA stock. During the lockdowns and the new normal, this entertainment platform helped while away the hours when other options were off the table.Despite its dominance in gaming, Nvidia would like to let you know that its one of the leaders in artificial intelligence stocks as well. The companys partnership with Walmart (NYSE:WMT) illustrates this relationship perfectly. As a big-box retailer, Walmart must make critical decisions all the time about their inventory: how much to buy, when to ship them out and to which stores, among countless other concerns.Fortunately, Walmart has advanced data analytics software that references back decades of data for hundreds of millions of products. But all that data processing requires sophisticated hardware otherwise, youre not going anywhere. Thats where Nvidia comes in with its graphics processors. Sure, theyre best known for their gaming applications, but they can do so much more.The 7 Best Semiconductor Stocks to Buy TodayNot surprisingly, NVDA stock has significant links to other burgeoning industries, such as self-driving technologies and the blockchain. Therefore, youll want to keep this on your short list of artificial intelligence stocks to buy.Tencent (TCEHY)Source: StreetVJ / Shutterstock.comTaking aside the politics, if you want to broaden your portfolio of artificial intelligence stocks, you should look at China. Companies like Tencent really are in an enviable position. For one, Tencents home market has blossomed into a technological powerhouse. Second, Chinas massive population means ample room for growth, increased connectivity and the biggest data goldmine.Further, Tencent has wide-reaching ambitions regarding its AI initiatives. As an internet content and social media network provider, the company is finetuning personalized advertisements and suggestions for its millions of users. In addition, Tencent is pursuing more serious endeavors, such as medical AI applications. Here, the idea is to use technology to help physicians detect and prevent the spread of disease.With the coronavirus having originated from China as President Trump reminds us every day this application seems very relevant for TCEHY stock.Of course, nothing can be divorced from politics these days and so it is with Tencent. As the owner of WeChat, the messaging/payments app has come under fire from the Trump administration. And that might mean TCEHY stock is on shaky ground, at least until we figure out who will run our nation on Nov. 3. Still, the opportunity for upside is tantalizing because of the aforementioned attributes of the home market.Match Group (MTCH)Source: ShutterstockInvariably, analyses of artificial intelligence stocks typically involve high-scale solutions. Over this list, weve covered the impact that AI can have on our purchasing decisions, interactions with machines, forecasting inventory demand and improving health outcomes. But AI doesnt have to be so serious. Instead, it can help with that age-old longing for love.Thats right, for those of who want to give Cupid an assist, online dating apps, such as those under the Match Group umbrella, may help accelerate your search for a soulmate. But what if Cupid needs help too? Increasingly, the mythical god has turned to artificial intelligence to help provide appropriate matchups.In a way, this is the probably the most ingenious use of AI. By now, many of these dating sites and apps have collected an enormous amount of behavioral data. Thats also due to the stigma of online dating fading away. Plus, with the novel coronavirus disrupting offline dating, Match is one of the viable places to go. That right there is a great reason to consider MTCH stock.10 ESG Stocks to Buy for a Brighter FutureBetter yet, Match is wising up to the power of AI to promote a safe dating environment. The company invested in Noonlight to provide safety features such as location tracking in case a meetup goes awry. Thats smart thinking, which should separate MTCH stock from other social networking investments.Trade Desk (TTD)Source: BrightSpace / Shutterstock.comWell before the pandemic, the cord-cutting phenomenon was placing increased pressure on traditional cable TV providers. With the advent of connected TV and streaming services, these innovations sparked never-before-seen capabilities, such as on-demand viewing. Instead of people revolving their lives around content scheduling (as in linear TV), the new generation of entertainment adapted to the individual.Following the coronavirus impact, the pressure to cut the cord intensified for many households. This was especially true during the early days of the crisis, when new content offerings were thin but the bills kept piling up. But pandemic or not, streaming and connected TV is here to stay. And that makes Trade Desk a relevant idea among artificial intelligence stocks.Primarily, the company utilizes AI algorithms to maximize advertisers return for their connected TV dollars. Thats much easier now because Trade Desk has access to a wealth of viewership data. As a result, its able to pinpoint which advertising strategies will work best, bolstering the narrative for TTD stock.Further, with live sports returning, Trade Desk may have an opportunity to evangelize its services. Because of the added cord-cutting pressures, the live sports streaming audience has probably increased significantly. That plays into the hands of TTD stock, where the underlying company can help advertisers plan for the possibility of games that go into overtime, which will likely feature a substantial uptick in engaged viewers.On the date of publication, Josh Enomoto did not have (either directly or indirectly) any positions in the securities mentioned in this article.A former senior business analyst for Sony Electronics, Josh Enomoto has helped broker major contracts with Fortune Global 500 companies. Over the past several years, he has delivered unique, critical insights for the investment markets, as well as various other industries including legal, construction management, and healthcare.More From InvestorPlaceWhy Everyone Is Investing in 5G All WRONGAmericas #1 Stock Picker Reveals His Next 1,000% WinnerRevolutionary Tech Behind 5G Rollout Is Being Pioneered By This 1 CompanyCould Tiny Super Battery Kill Big Tech?The post 7 Artificial Intelligence Stocks to Buy for October appeared first on InvestorPlace.

Continued here:
Innovative Gx Laboratories Announces the Grand Opening of Its Molecular Diagnostic Laboratory in Texas - Yahoo Finance

Healthcare’s future resides in genetic research and genomic testing – Utah Business – Utah Business

Posted on August 29, 2021 by Danzig

Someday there will be an app on your smartphone that knows exactly what medicine will work best for you. It will warn you of your risk for developing certain diseases and offer a personalized plan for preventing them. It will even be able to determine your likelihood of passing on certain conditions to your unborn baby. Ultimately, it will increase your lifespan and help you enjoy a higher quality of life.

This will all be possible because of one thing: genomics.

To understand genomics, you first have to understand thedifference between genes and genomes.

Genomicsis the study of genomes specifically how your DNA functions and interacts within your body. Through genomics, scientists and researchers have sought to better understand how a persons genes interact with each other and with their environment.

Precision genomicstakes this one step further. Using genomic information, doctors can create more personalized healthcare options for individuals battling illness and disease.

Human beings are more alike than they are different. In fact,research showsthat humans are 99.9 percent identical in their genetic makeup. Understanding the remaining 0.1 percent holds the clues about detecting and preventing certain diseases.Thats where genomics comes in.

Genetic testing looks for inherited mutations in healthy cells.Genomic sequencinglooks at genetic mutations in unhealthy cells.Heres why that matters for your health:

In the past, if you were diagnosed with cancer, your doctor would most likely recommend a standard form of treatment that worked for most people. But these days, healthcare providers can provide acustom-fit treatmentthats based on your specific DNA. They do this by identifying mutations in certain cells.

Dr. Lincoln Nadauld,chief of precision health and academics at Intermountain Healthcare, put it simply. [Precision genomics] means picking treatments for patients with cancer based on DNA changes in their cancer, he says.

And having more effective, personalized treatment plans means:

Genomics also helps identify certain health risks because these factors play a role in nine out of 10 of theleading causes of death.Knowing youre at risk for diabetes or heart disease could help you take steps to prevent their onset.

Genomic medicine is changing the way doctors approach individualized patient care particularly in the fields of oncology, pharmacology, and rare or genetic diseases.

1.Cancer treatment.Precision genomics improves cancer treatment by providing moretargeted therapiesthat are personalized to each patient.

Intermountain has long been recognized for its role in leading cancer research. By collaborating with other institutions and sharing data, doctors are learning how to best treat cancer. And now Intermountain is leading the charge in precision genomics research.

Through a variety of clinical trials, researchers study how different cancers respond to combinations of targeted treatment and immunotherapy (treatments that stimulate a persons immune system to fight cancer).

2. Matching medication.If youve ever been concerned about the potential side effects of certain medications, pharmacogenomics can help.

Pharmacogenomicsis the study of how genes can affect a persons response to medication. By studying your DNA, doctors can discover which drugs are most likely to work for you and what dosage your body might need. (This includes antidepressants, opioid pain relievers, heart medications, anti-inflammatories, antidiabetics, medications used before and after surgery, and more.) This process is called RxMatch testing. Pinpointing which drugs would be most effective for patients reduces the likelihood of negative side effects and repeat doctor visits.

3. Genetic counseling.Worried that cancer might run in your family? Want to know your chances of passing on conditions to your children?A genetic counselorcan assess your family history and genetic test results to determine if youre at risk of developing certain health conditions.

The National Society of Genetic Counselorssuggests the following as good reasons to see a genetic counselor:

The ultimate goal with each of these is to help patients live longer and better lives. The more you understand about your DNA, the better your chances for a high-quality life.

To see genomics in action, consider one Intermountainpatients story.

In 2013, Telitha Greiner had a colonoscopy that revealed cancer spread to her liver and lungs. A friend suggested she travel to St. George to see Dr. Nadauld, whose focus was extending the lives and quality of life for stage four cancer patients.

The genetic testing done by Dr. Nadauld revealed that one of the cancer drugs I was taking that had particularly painful side effects was not genetically effective, Greiner says. It wasnt doing me any good and caused a very painful skin condition. I am so grateful to know that I dont have to take it anymore and for the state-of-the-art care I am receiving at Intermountain.

Like Greiner, many patients have benefited fromIntermountain Precision Genomics.Its state-of-the-artTheraMap testoffers genetic testing for patients who havent found success with traditional treatment options.

For Nadauld, each individual patient serves as a reminder of how important this research is.

Though a lot of good has come from genetic research, theres still much work to be done. With further research prediction, prevention, and treatment can improve much faster. Thats where you have an opportunity to make a difference.

In order to discover new connections betweengeneticsand human disease, doctors and researchers are asking people to participate in theHerediGene: Population Study.This study is asking for 500,000 participants, including 50,000 children, over the course of five years.

Last year, Dr. Nadauld addressed the importance of HerediGene participation in a podcast episode ofThanks for Asking.

Theres extraordinary interest in this, primarily because it offers the opportunity to understand populations better and to start to predict the health across entire populations, he says. What that means is we could start to predict individuals in a population who might be at risk to get some forms of cancer or other individuals who might be at risk to have a heart attack or a stroke or to develop diabetes. And if we can predict that, then maybe we can work with those individuals to prevent some of those things from happening.

HerediGene participants are helping us piece together clues that will help doctors save lives and that could include your own.

If youre interested in furthering genetic research and benefiting future generations,find a participating location near you.No appointment is necessary. Participation is voluntary and provided at no cost to you.

Genomics is changing the way doctors practice medicine and treat disease. In the coming years, many more people will have access to targeted therapies and medicine designed specifically for them.

But healthcare is not one-size-fits-all. Finding the best healthcare solution for you or your loved ones requires open and honest conversations with your doctor.

If you think precision medicine could be right for you, here are a few suggestedtips for talking with your healthcare provider:

If you have questions or youre interested in learning more,visit the Intermountain Precision Genomics page for patients.

Read the original post:
Healthcare's future resides in genetic research and genomic testing - Utah Business - Utah Business

Foundation Medicine, Epic collaboration focuses on genomics for precision oncology – Healthcare IT News

Posted on August 29, 2021 by Danzig

Foundation Medicine this week announced a new partnership with Epic to integrate its genomic profiling and testing services into its electronic health system.

WHY IT MATTERSCambridge, Massachusetts-based Foundation Medicine offers a suite of genomic profiling assays to identify the molecular alterations of patients' cancers and match them with targeted therapies and clinical trials. With this new collaboration customers will be able to electronically order Foundation tests within the Epic network, directly within the EHR.

The collaboration is aimed at oncology practices, hospitals, academic medical centers and health systems, to enable easy access to clinical and genomic information for more streamlined clinical decision support.

With the new integration, clinical teams can place orders for Foundation's comprehensive genomic profiling tests and receive and view results within their existing EHR workflow. The aim is to also reduce data entry while offering faster actionable insights to help physicians guide treatment planning.

The integration is expected to be available in 2022. Foundation Medicine says it is also partnering with organizations using non-Epic EHRs to meet their own oncology needs.

THE LARGER TRENDThis isn't the only news this week about genomics-focused precision decision support. On Wednesday, AccessDX Holdings, developer of lab diagnostics and CDS tools, announced its acquisition of 2bPrecise which helps health systems advance precision medicine by aggregating genomics from labs and clinical information from EHRs from Allscripts.

Earlier this month, in an interview with Healthcare IT News at HIMSS21, Dr. Robert Bart, chief medical information officer at Pittsburgh-based UPMC, highlighted the necessity of digitized discrete data, integrated into EHR workflows, for precision medicine to work.

"We really think that, when you're moving into the world of pharmacogenomics or genomic medicine, that you really need to embed decision support into your electronic health record," he said.

"And you have to really insist on taking the results only in digital format. So if we get external results from reference labs, we don't want PDFs. We want to actually discrete data, so we can trigger the decision support, as well as provide supporting content for interpretation by our clinicians and the content so the patient can understand what that result means for them."

ON THE RECORD"In order to bring the reality of precision medicine to more cancer patients, we need to simplify the process for getting oncologists access to the genomic insights they need for targeted treatment planning," said Kathleen Kaa, interim chief commercial officer at Foundation Medicine, in a statement about the new Epic integrations. She called it "one of our key efforts to improve the process for ordering our tests so care teams can focus on providing the best treatment for their patients."

Twitter:@MikeMiliardHITNEmail the writer:mike.miliard@himssmedia.comHealthcare IT News is a HIMSS publication.

Read the original:
Foundation Medicine, Epic collaboration focuses on genomics for precision oncology - Healthcare IT News

Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market: Development Factors and Investment Analysis by Leading Manufacturers -…

Posted on September 18, 2020 by Danzig

Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market (2020-2026) report highlights Significant dynamics and in-depth analysis of the market segment with concentrating on factual data, present industry activities, growth opportunities, new product inventions, and market forecast for the future prospective of time along with leading market players, market study based on several regions, and extensive product. Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market report can function as an assistive reference point for helping individuals as well as businesses from this segment.

The report on Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market comprises an in-depth analysis of key global developments that will be beneficial to businesses operating in this industry. The report delivers a clear understanding of the major trends and forthcoming market prospects to facilitate the making of effective business strategies.

Request Sample Copy of this Report @ https://www.theresearchprocess.com/request-sample/5146

The study identifies the opportunities and growth drivers that will impact the remuneration scale of the industry over the analysis period. It also entails the threats and challenges tackled by the industry along with solutions to subdue their impact.

Request Sample Copy of this Report @ https://www.theresearchprocess.com/request-sample/5146

The report offers a comparison of present and past market outlook to deduce the growth rate of this industry vertical over the study period. Besides, it evaluates the COVID-19 pandemic impact on overall and regional markets to determine methodologies that can potentially yield significant returns for industry participants.

Main highlights from table of contents:

Product landscape

Application scope

Geographical terrain

Competitive outlook

In summary, the Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market assessment has been performed at a granular level through various segmentations, while keeping track of other crucial aspects like supply chain and sales channel comprising of details about the downstream buyers, upstream suppliers, raw materials, and distributors in the industry.

Key Benefits For Stakeholders

The Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market report provides extensive qualitative insights on the potential and niche segments or regions exhibiting favorable growth.

The report provides an extensive analysis of the current and emerging market trends and opportunities in the global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market.

A comprehensive analysis of the factors that drive and restrict the growth of the Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market is provided.

An extensive analysis of the Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market is conducted by following key product positioning and monitoring the top competitors within the market framework.

The report provides a detailed qualitative and quantitative analysis of current trends and future estimations that help evaluate the prevailing market opportunities.

Request Customization on This Report @ https://www.theresearchprocess.com/request-for-customization/5146

See original here:
Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market: Development Factors and Investment Analysis by Leading Manufacturers -...

Sanford genetics group shares benefits of custom kids’ care – Sanford Health News

Posted on January 22, 2021 by Danzig

Pharmacogenetics, or precision medicine, is still new to many pediatric providers despite its documented benefits, according to an article the Sanford Childrens Genomic Medicine Consortium published recently in The Pharmacogenomics Journal.

Pharmacogenetics uses a persons DNA to help providers choose the best medicine and dosage of medicine. And there are plenty of opportunities to use genetic traits in pediatrics, the group wrote.

Theres evidence that pharmacogenetics benefit pediatric oncology, pain management, organ transplantation, and immunosuppression, according to the journal article. Additionally, advances in technology have made it easier to study complete genomes, and providers can use that information to improve health care for children.

Ten hospitals have signed on to the consortium to rapidly integrate genetics and genomics into primary and specialty pediatric care.

Above all, the mission of the consortium is to efficiently manage resources in genetics and genomics, perform cutting-edge research and education and bring genomic medicine into pediatric practice. This will help set the standard for precision medicine in childrens health care.

The 10 member hospitals are:

A previous innovation project funded by the consortium was a study of the outcomes of rapid whole genomic sequencing in critically ill newborn infants. Another previous study evaluated the routine use of an extensive, pediatric-focused, next generation sequencing panel in the diagnosis of childhood cancers.

Posted In Children's, Company News, Genetics

Originally posted here:
Sanford genetics group shares benefits of custom kids' care - Sanford Health News

Sports and Fitness Genomics and Pharmacogenomics Market Size And Forecast (2020-2026)| With Post Impact Of Covid-19 By Top Leading Players- GeneDx,…

Posted on February 10, 2021 by Danzig

This report studies the Sports and Fitness Genomics and Pharmacogenomics Market with many aspects of the industry like the market size, market status, market trends and forecast, the report also provides brief information of the competitors and the specific growth opportunities with key market drivers. Find the complete Sports and Fitness Genomics and Pharmacogenomics Market analysis segmented by companies, region, type and applications in the report.

The report offers valuable insight into the Sports and Fitness Genomics and Pharmacogenomics market progress and approaches related to the Sports and Fitness Genomics and Pharmacogenomics market with an analysis of each region. The report goes on to talk about the dominant aspects of the market and examine each segment.

Key Players: GeneDx, Assurex Health, 23andMe, Teva Pharmaceutical Industries, Future Science Group, Myriad Genetics, Pathway Genomics, and GeneTech

The final report will add the analysis of the Impact of Covid-19 in this report Sports and Fitness Genomics and Pharmacogenomics industry.

Get a Free Sample Copy @ https://www.reportsandmarkets.com/sample-request/global-sports-and-fitness-genomics-and-pharmacogenomics-market-report-2020-by-key-players-types-applications-countries-market-size-forecast-to-2026-based-on-2020-covid-19-worldwide-spread?utm_source=neighborwebsj&utm_medium=36

The global Sports and Fitness Genomics and Pharmacogenomics market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Sports and Fitness Genomics and Pharmacogenomics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type, and by Application for the period 2020-2026.

Market Segment by Regions, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia and Italy)

Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

South America (Brazil, Argentina, Colombia etc.)

Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Research objectives:

To study and analyze the global Sports and Fitness Genomics and Pharmacogenomics market size by key regions/countries, product type and application, history data from 2013 to 2017, and forecast to 2026.

To understand the structure of Sports and Fitness Genomics and Pharmacogenomics market by identifying its various sub segments.

Focuses on the key global Sports and Fitness Genomics and Pharmacogenomics players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in next few years.

To analyze the Sports and Fitness Genomics and Pharmacogenomics with respect to individual growth trends, future prospects, and their contribution to the total market.

To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).

To project the size of Sports and Fitness Genomics and Pharmacogenomics submarkets, with respect to key regions (along with their respective key countries).

To analyze competitive developments such as expansions, agreements, new product launches and acquisitions in the market.

To strategically profile the key players and comprehensively analyze their growth strategies.

The report lists the major players in the regions and their respective market share on the basis of global revenue. It also explains their strategic moves in the past few years, investments in product innovation, and changes in leadership to stay ahead in the competition. This will give the reader an edge over others as a well-informed decision can be made looking at the holistic picture of the market.

Table of Contents: Sports and Fitness Genomics and Pharmacogenomics Market

Chapter 1: Overview of Sports and Fitness Genomics and Pharmacogenomics Market

Chapter 2: Global Market Status and Forecast by Regions

Chapter 3: Global Market Status and Forecast by Types

Chapter 4: Global Market Status and Forecast by Downstream Industry

Chapter 5: Market Driving Factor Analysis

Chapter 6: Market Competition Status by Major Manufacturers

Chapter 7: Major Manufacturers Introduction and Market Data

Chapter 8: Upstream and Downstream Market Analysis

Chapter 9: Cost and Gross Margin Analysis

Chapter 10: Marketing Status Analysis

Chapter 11: Market Report Conclusion

Chapter 12: Research Methodology and Reference

Key questions answered in this report

What will the market size be in 2026 and what will the growth rate be?

What are the key market trends?

What is driving this market?

What are the challenges to market growth?

Who are the key vendors in this market space?

What are the market opportunities and threats faced by the key vendors?

What are the strengths and weaknesses of the key vendors?

Get complete Report @ https://www.reportsandmarkets.com/sample-request/global-sports-and-fitness-genomics-and-pharmacogenomics-market-report-2020-by-key-players-types-applications-countries-market-size-forecast-to-2026-based-on-2020-covid-19-worldwide-spread?utm_source=neighborwebsj&utm_medium=36

About Us:

Reports and Markets is not just another company in this domain but is a part of a veteran group called Algoro Research Consultants Pvt. Ltd. It offers premium progressive statistical surveying, market research reports, analysis & forecast data for a wide range of sectors both for the government and private agencies all across the world. The database of the company is updated on a daily basis. Our database contains a variety of industry verticals that include: Food Beverage, Automotive, Chemicals and Energy, IT & Telecom, Consumer, Healthcare, and many more. Each and every report goes through the appropriate research methodology, Checked from the professionals and analysts.

Sanjay Jain

Manager Partner Relations & International Marketing

http://www.reportsandmarkets.com

Ph: +1-352-353-0818 (US)

https://neighborwebsj.com/

See the article here:
Sports and Fitness Genomics and Pharmacogenomics Market Size And Forecast (2020-2026)| With Post Impact Of Covid-19 By Top Leading Players- GeneDx,...

Identification of Intrinsic Drug Resistance and Its Biomarkers in High-Throughput Pharmacogenomic and CRISPR Screens – DocWire News

Posted on November 19, 2020 by Danzig

This article was originally published here

Patterns (N Y). 2020 Jul 2;1(5):100065. doi: 10.1016/j.patter.2020.100065. eCollection 2020 Aug 14.

ABSTRACT

High-throughput drug screens in cancer cell lines test compounds at low concentrations, thereby enabling the identification of drug-sensitivity biomarkers, while resistance biomarkers remain underexplored. Dissecting meaningful drug responses at high concentrations is challenging due to cytotoxicity, i.e., off-target effects, thus limiting resistance biomarker discovery to frequently mutated cancer genes. To address this, we interrogate subpopulations carrying sensitivity biomarkers and consecutively investigate unexpectedly resistant (UNRES) cell lines for unique genetic alterations that may drive resistance. By analyzing the GDSC and CTRP datasets, we find 53 and 35 UNRES cases, respectively. For 24 and 28 of them, we highlight putative resistance biomarkers. We find clinically relevant cases such as EGFRT790M mutation in NCI-H1975 or PTEN loss in NCI-H1650 cells, in lung adenocarcinoma treated with EGFR inhibitors. Interrogating the underpinnings of drug resistance with publicly available CRISPR phenotypic assays assists in prioritizing resistance drivers, offering hypotheses for drug combinations.

PMID:33205120 | PMC:PMC7660407 | DOI:10.1016/j.patter.2020.100065

See the original post here:
Identification of Intrinsic Drug Resistance and Its Biomarkers in High-Throughput Pharmacogenomic and CRISPR Screens - DocWire News

Drug Discovery Technologies Industry Market including top key players Luminex Corporation, Bayer Healthcare AG, Novartis AG – PRnews Leader

Posted on November 20, 2020 by Danzig

Drug Discovery Technologies Industry Market Forecast 2029: Revenue, Size & Growth

Global Drug Discovery Technologies Industry MarketForecast till 2029research includes reliable economic, international, and country-level forecasts and analysis. It offers a holistic view of the competitive market and thorough analyses of the supply chain to help companies identify closely significant trends in the company practices seen in the sector. Major Companies listed in this Reports areLuminex Corporation, Bayer Healthcare AG, Novartis AG, Agilent Technologies, Inc, Affymetrix Inc., Astrazeneca plc, Albany Molecular Research Inc., GE Healthcare Ltd., Abbott Laboratories, Inc., Arqule Inc..

Free Sample Report & Pie Charts Available@jcmarketresearch.com/report-details/1139660/sample

Regional Breakout for Drug Discovery Technologies Industry Market: North America XXX million $, Europe XXX million $, Asia XXX million $ & Rest of World.

OverviewDrug Discovery Technologies Industry Market including Types & Application:

North America:United States, Canada, and MexicoSouth & Central America:Argentina, Chile, and BrazilMiddle East & Africa:Saudi Arabia, UAE, Turkey, Egypt and South AfricaEurope:UK, France, Italy, Germany, Spain, and Russia

Application: Biopharmaceutical companies, Pharmaceutical companies, Research institutes, Biotech companies

Types:Biochips, High throughput screening, Pharmacogenomics, Genomics, Bioanalytical instruments, Bioinformatics, Nanotechnology, Others (RNAi, combinatorial chemistry)

Drug Discovery Technologies Industry Market Leading Competition:In this section, the report provides information on Competitive situations and trends including merger and acquisition and expansion, market shares of the top ten players, and market concentration rate. Readers could also be provided with production, revenue, and average price shares by manufacturers.

Get Special Discount in Covid-19 @jcmarketresearch.com/report-details/1139660/discount

Research Methodology:

The market engineering process uses a top-down and bottom-up approach and several data triangulation methods to evaluate and validate the size of the entire market and other dependent sub-markets listed in Drug Discovery Technologies Industry report. Numerous qualitative and quantitative analyzes have been conducted in the market engineering process to list key information / insights. The major players in the market were identified through the second survey and the market rankings were determined through the first and second surveys.

Primary Research:

During the first survey, we interviewed various key sources of supply and demand to obtain qualitative and quantitative information related to Drug Discovery Technologies Industry report. Key supply sources include key industry participants, subject matter specialists from key companies, and consultants from several major companies and organizations active in the digital signage market.

Secondary Research:

The second study was conducted to obtain key information on the supply chain of the Drug Discovery Technologies Industry industry, the markets currency chain, pools of major companies, and market segmentation, with the lowest level, geographical market, and technology-oriented perspectives. Secondary data was collected and analyzed to reach the total market size, which was verified by the first survey.

Global Drug Discovery Technologies Industry Market Detailed study of each point:

TheDrug Discovery Technologies Industry Marketstudy offers a comprehensive overview of the current market and forecasts by 2020-2029 to help identify emerging business opportunities on which to capitalize.

The report provides an in-depth review of industry dynamics in Drug Discovery Technologies Industry, including existing and potential developments to represent prevailing consumer pockets of investment.

The report provides details concerning key drivers, constraints and opportunities and their effect on the Drug Discovery Technologies Industry market.

Industry players Luminex Corporation, Bayer Healthcare AG, Novartis AG, Agilent Technologies, Inc, Affymetrix Inc., Astrazeneca plc, Albany Molecular Research Inc., GE Healthcare Ltd., Abbott Laboratories, Inc., Arqule Inc. strategic analysis and industry position in the global Drug Discovery Technologies Industry market;

The report elaborates on the SWOT analysis and Porters Five Forces model.

The market-study value chain review gives a good view of the positions of the stakeholders.

GetCustomized Report Toc @:jcmarketresearch.com/report-details/1139660/enquiry

Major Highlights of Drug Discovery Technologies Industry Market in Covid-19 pandemic covered in report:

Market Competition by key manufacturers in the Drug Discovery Technologies Industry industry. Discussed Sourcing strategies, industrial chain information and downstream buyers data. Distributors and traders on Drug Discovery Technologies Industry marketing strategy analysis focusing on region wise needs in covid-19 pandemic. Vendors who are providing a wide range of product lines and intensifying the competitive scenario in Drug Discovery Technologies Industry covid-19 crisis. Also highlights of the key growth sectors of Drug Discovery Technologies Industry market and how they will perform in coming years.

Buy Full Copy Global Drug Discovery Technologies Industry Report 2029 @jcmarketresearch.com/checkout/1139660

** The demand is measured on the basis of the weighted average sale price (WASP), which requires the manufacturers taxes. The currency conversions that were used to construct this study were determined using a given annual average rate of currency exchange from 2020.

About Author:

JCMRglobal research and market intelligence consulting organization is uniquely positioned to not only identify growth opportunities but to also empower and inspire you to create visionary growth strategies for futures, enabled by our extraordinary depth and breadth of thought leadership, research, tools, events and experience that assist you for making goals into a reality. Our understanding of the interplay between industry convergence, Mega Trends, technologies and market trends provides our clients with new business models and expansion opportunities. We are focused on identifying the Accurate Forecast in every industry we cover so our clients can reap the benefits of being early market entrants and can accomplish their Goals & Objectives.

JC MARKET RESEARCH

Mark Baxter (Head of Business Development)

Phone:+1 (925) 478-7203

Email:[emailprotected]

Connect with us at LinkedIn

http://www.jcmarketresearch.com

See the article here:
Drug Discovery Technologies Industry Market including top key players Luminex Corporation, Bayer Healthcare AG, Novartis AG - PRnews Leader

Sports and Fitness Genomics and Pharmacogenomics Industry Market 2021 In-depth Analysis, Growth with Forecast 2027:Assurex Health, Teva Pharmaceutical…

Posted on January 20, 2021 by Danzig

This contemporary, modern market research compilation is a systematic overview of the overall market status and structure prevalent in global Sports and Fitness Genomics and Pharmacogenomics market and their rampant implications upon holistic growth trajectory and further probabilities in the near future. The report is based on extensive primary and secondary research initiatives and the insights thus achieved have been stacked systematically aided by several graphs, tables and charts to encourage seamless comprehension. The report sheds ample light into both past and current developments to infer futuristic probabilities. Relevant understanding on market prognosis, trends, policy updates and current development statistics have all been highlighted in thorough detail for quick deductions and subsequent investment discretion by Orbis Pharma Reports.

Get sample copy of [emailprotected] https://www.orbispharmareports.com/sample-request/91270

Major Company Profiles operating in the Sports and Fitness Genomics and Pharmacogenomics Market:

Assurex HealthTeva Pharmaceutical IndustriesFuture Science GroupPathway Genomics23andMeGeneDxMyriad GeneticsGeneTechMajor Types CoveredMicroarraySequencingPolymerase Chain ReactionOthers

By the product type, the market is primarily split into

MicroarraySequencingPolymerase Chain ReactionOthers

By the application, this report covers the following segments

OncologyCardiologyNeurological DisordersOthers

Browse the complete report @ https://www.orbispharmareports.com/2015-2027-global-sports-and-fitness-genomics-and-pharmacogenomics-industry-market-research-report-segment-by-player-type-application-marketing-channel-and-region/

Regional Overview:This versatile research report presentation on global Sports and Fitness Genomics and Pharmacogenomics market, presented by Orbis Pharma Reports has maintained highest parameters of research practices to unravel crucial details. Holistic geographical diversifications have been carefully analyzed and prominent growth centers have been categorically flagged to maintain uniform growth trends.Besides entailing region-specific details, country-wise detailing have also been included to encourage rapid decision making. For maximum reader discretion and subsequent investment decisions, this report on global Sports and Fitness Genomics and Pharmacogenomics market as assessed by Orbis Pharma Reports reveals Germany, France, Italy, UK as ideal growth hotspots, followed by American growth hubs such as Mexico, Brazil, US and Canada. MEA countries and APAC nations have also been thoroughly scanned to understand growth patterns, competition intensity as well as vendor activities across these growth points.

For Any Query on the Sports and Fitness Genomics and Pharmacogenomics Market: https://www.orbispharmareports.com/enquiry-before-buying/91270

Decoding Segment Specifications:The report by Orbis Pharma Reports on global Sports and Fitness Genomics and Pharmacogenomics market encourages complete stratification of the market in terms of segments to understand growth patterns. All prominent segments highlighted in the report have been assessed based on set parameters such as capital diversion, inventory management as well as utility diversification, besides exploring supply chain developments to understand segment potential in growth progression. Each of the segment identified has been assessed on the basis of various market parameters to explore growth projections and likelihood. The report is based on complete SWOT and PESTEL assessment, followed by PORTERs Five Forces assessment and evaluation of all DROT factors. These details are highly crucial to encourage appropriate investment decisions on the part of inquisitive readers and aspirational investors.Orbis Pharma Reports also sketches the prevalent competition landscape, isolating frontline players as well as their growth proficient business decisions. Based on these business decisions, this report helps investors to deliver lucrative business decisions.

About Us :

At Orbispharma we curate the most relevant news stories, features, analysis and research reports on the important challenges undertaken by the pharmaceutical and related sectors. Our editorial philosophy is to bring you sharp, focused and informed perspective of industries, the end users and application of all upcoming trends into the pharma sector. Orbispharma believes in conversations that can bring a change in one of the most crucial economic sectors in the world. With these conversations we wish our customers to make sound business decisions with right business intelligence.

Read the original here:
Sports and Fitness Genomics and Pharmacogenomics Industry Market 2021 In-depth Analysis, Growth with Forecast 2027:Assurex Health, Teva Pharmaceutical...

Global Precision Medicine Market 2020-2030: Focus on Ecosystem, Technology, Application, and Competitive Landscape – ResearchAndMarkets.com – Benzinga

Posted on October 4, 2020 by Danzig

The "Global Precision Medicine Market: Focus on Ecosystem, Technology, Application, Country Data (21 Countries), and Competitive Landscape - Analysis and Forecast, 2020-2030" report has been added to ResearchAndMarkets.com's offering.

Global Precision Medicine Market to Reach $278.61 Billion by 2030

Precision medicine refers to the medicine developed as per an individual's genetic profile. It provides guidance regarding the prevention, diagnosis, and treatment of diseases. The segmentation of the population is done depending on the genome structure of the individuals and their compatibility with a specific drug molecule.

In the precision medicine market, the application of molecular biology is to study the cause of a patient's disease at the molecular level, so that target-based therapies or individualized therapies can be applied to cure the patient's health-related problems.

This industry is gaining traction due to the increasing awareness about healthcare among individuals, integration of smart devices such as smartphones and tablets into healthcare, and increasing collaborations and agreements of IT firms with the diagnostics and biopharmaceutical companies for the development of precision diagnostic tools.

Within the research report, the market is segmented on the basis of product type, ecosystem application, and region, which highlight value propositions and business models useful for industry leaders and stakeholders. The research also comprises country-level analysis, go-to-market strategies of leading players, future opportunities, among others, to detail the scope and provide 360-degree coverage of the domain.

Key Topics Covered:

1 Product Definition

2 Research Scope

3 Research Methodology

4 Global Precision Medicine Market Overview

4.1 Market Definition

4.2 Precision Medicine: A Frontier in the Genesis of Patient-centric Medicine

4.3 Precision Medicine: Remodeling the One-Size-Fits-All Theory to Individually Tailored Therapy

4.4 Initiatives and Programs

4.5 Precision Medicine: Enabling Technologies and Applications

4.5.1 Innovators

4.5.1.1 3D DNA Printing

4.5.1.1.1 Introduction

4.5.1.1.2 Role of 3D DNA Printing

4.5.1.2 RNA-Seq

4.5.1.2.1 Introduction

4.5.1.2.2 Role of RNA-Seq in Precision Medicine

4.5.1.2.3 Key Players

4.5.1.3 4D Molecular Imaging

4.5.1.3.1 Introduction

4.5.1.3.2 Role of 4D Molecular Imaging in Precision Medicine

4.5.1.3.3 Key Players

4.5.2 Early Adopters

4.5.2.1 CRISPR

4.5.2.1.1 Introduction

4.5.2.1.2 Role of CRISPR in Precision Medicine

4.5.2.1.3 Key Players

4.5.2.2 Blockchain

4.5.2.3 Imaging Informatics

4.5.3 Early Majority

4.5.3.1 Artificial Intelligence (AI)

4.5.3.2 Circulating Free DNA (cfDNA)

4.5.3.3 Big Data

4.5.3.4 Next-Generation Sequencing (NGS)

4.5.3.5 Health Informatics

4.5.3.6 Bioinformatics

4.5.4 Late Majority

4.5.4.1 Polymerase Chain Reactions (PCR)

4.5.4.2 Microarray

4.6 COVID-19 Impact on the Global Precision Medicine Market

5 Market Dynamics

5.1 Overview

5.2 Market Drivers

5.2.1 Advancement of Sequencing Technologies

5.2.2 Rising Prevalence of Chronic Diseases

5.2.3 Growing Demand for Preventive Care

5.2.4 Shifting the Significance in Medicine, from Reaction to Prevention

5.2.5 Reducing Adverse Drug Reactions Through Pharmacogenomics Test

5.2.6 Potential to Reduce the Overall Healthcare Cost Across the Globe

5.3 Market Restraints

5.3.1 Unified Framework for Data Integration

5.3.2 Limited Knowledge about Molecular Mechanism/ Interaction

5.3.3 Lack of Robust Reimbursement Landscape

5.3.4 Regulatory Hurdles

5.4 Market Opportunities

5.4.1 Targeted Gene Therapy

5.4.2 Expansion into the Emerging Markets

5.4.3 Collaboration and Partnerships Across Value Chain to Accelerate the Market Entry

6 Industry Insights

6.1 Patent Analysis

6.2 Legal Requirements and Regulations

6.3 Pipeline Analysis

6.4 Legal Requirements and Framework by the FDA

6.5 Legal Requirements and Framework by the EMA

6.6 Legal Requirements and Framework by the MHLW

7 Competitive Landscape

7.1 Synergistic Activities

7.1.1 Product launches, Enhancements, and Upgradation

7.1.2 Product Approvals

7.1.3 Mergers and Acquisitions

7.1.4 Business Expansion

7.2 Market Share Analysis

7.2.1 Market Share Analysis by Applied Sciences, 2019

7.2.2 Market Share Analysis by Precision Diagnostics, 2019

7.2.3 Market Share Analysis by Precision Therapeutics, 2019

7.2.4 Market Share Analysis by Digital Health and IT, 2019

8 Global Precision Medicine Market (by Ecosystem)

8.1 Overview

8.2 Applied Sciences

8.2.1 Genomics

8.2.2 Global Precision Medicine Genomics Market (by Technology)

8.2.2.1 Polymerase Chain Reaction (PCR)

8.2.2.2 Next-Generation Sequencing (NGS)

8.2.2.3 Genome Editing

8.2.2.4 Other Technologies

8.2.3 Pharmacogenomics

8.2.4 Other Applied Sciences

8.3 Precision Diagnostics

8.3.1 Molecular Diagnostics (MDx)

8.3.2 Global Precision Medicine Molecular Diagnostics Market (by Type)

8.3.2.1 Non-Invasive Prenatal Testing (NIPT)

8.3.2.2 Companion Diagnostics

8.3.2.3 Liquid Biopsy

8.3.2.4 Other Molecular Diagnostics

Visit link:
Global Precision Medicine Market 2020-2030: Focus on Ecosystem, Technology, Application, and Competitive Landscape - ResearchAndMarkets.com - Benzinga

Global Genomic Cancer Panel and Profiling Markets Report 2021-2025: The Market is Moving Out of a Specialized Niche and Going Mainstream -…

Posted on November 19, 2020 by Danzig

Dublin, Nov. 19, 2020 (GLOBE NEWSWIRE) -- The "Genomic Cancer Panel and Profiling Markets by Cancer and Germline/Somatic Type with Screening Potential Market Size, Customized Forecasting/Analysis, and Executive and Consultant Guides 2021-2025" report has been added to ResearchAndMarkets.com's offering.

This report provides data that analysts and planners can use. Hundreds of pages of information including a complete list of Current 2020 United States Medicare Fee Payment Schedules to help understand test pricing in detail.

Forecast demand for new testing regimes or technologies. Make research investment decisions. Existing laboratories and hospitals can use the information directly to forecast and plan for clinical facilities growth.

Cancer Gene Panels and Genomic Profiling are quickly changing the diagnosis and treatment of cancers. The market is moving out of a specialized niche and going mainstream as Oncologists begin routinely using information on the hundreds of genes related to cancer. The market is exploding as physicians use all the information they can get in the battle against cancer. And there is a lot of information to be had. But the COVID-19 Pandemic has impacted the market.

Comprehensive panels, genomic profiling, high-risk breast cancer panels. Learn all about how players are jockeying for position in a market that is being created from scratch. And some players are already taking the lead. It is a dynamic market situation with enormous opportunity where the right diagnostic with the right support can command premium pricing. And the science is developing at the same time creating new opportunities with regularity. And the cost of sequencing continues to fall.

The report includes detailed breakouts for 18 Countries and 4 Regions.

Key Topics Covered:

Cancer Panel Market - Strategic Situation Analysis & COVID Update

1. Introduction and Market Definition 1.1 What are Cancer Gene Panels and Profiling? 1.2 The Sequencing Revolution 1.3 Market Definition 1.4 Methodology 1.5 A Spending Perspective on Clinical Laboratory Testing 1.5.1 An Historical Look at Clinical Testing

2. Market Overview 2.1 Players in a Dynamic Market 2.1.1 Academic Research Lab 2.1.2 Diagnostic Test Developer2.1.3 Instrumentation Supplier 2.1.4 Distributor and Reagent Supplier 2.1.5 Independent Testing Lab2.1.6 Public National/regional lab 2.1.7 Hospital lab 2.1.8 Physician Office Labs 2.1.9 Audit Body 2.1.10 Certification Body2.2 Oncogenomics2.2.1 Carcinogenesis2.2.2 Chromosomes, Genes and Epigenetics 2.2.2.1 Chromosomes 2.2.2.2 Genes 2.2.2.3 Epigenetics 2.2.3 Cancer Genes 2.2.4 Germline vs Somatic 2.2.5 Gene Panels, Single Gene Assays and Multiplexing 2.2.6 Genomic Profiling 2.2.7 The Comprehensive Assay 2.2.8 Changing Clinical Role 2.2.9 The Cancer Screening Market Opportunity2.3 Cancer Management vs. Diagnosis 2.3.1 The Role of Risk Assessment 2.3.2 Diagnosis 2.3.3 Managing 2.3.4 Monitoring 2.4 Phases of Adoption - Looking into The Future 2.5 Structure of Industry Plays a Part 2.5.1 Hospital Testing Share 2.5.2 Economies of Scale2.5.2.1 Hospital vs. Central Lab 2.5.3 Physician Office Lab's 2.5.4 Physician's and POCT

3. Market Trends3.1 Factors Driving Growth3.1.1 Level of Care 3.1.2 Companion Dx 3.1.3 Immuno-oncology 3.1.4 Liability3.1.5 Aging Population3.2 Factors Limiting Growth3.2.1 State of knowledge3.2.2 Genetic Blizzard. 3.2.3 Protocol Resistance3.2.4 Regulation and coverage 3.3 Instrumentation and Automation 3.3.1 Instruments Key to Market Share 3.3.2 Bioinformatics Plays a Role 3.4 Diagnostic Technology Development3.4.1 Next Generation Sequencing Fuels a Revolution 3.4.2 Single Cell Genomics Changes the Picture 3.4.3 Pharmacogenomics Blurs Diagnosis and Treatment3.4.4 CGES Testing, A Brave New World 3.4.5 Biochips/Giant magnetoresistance based assay

4. Cancer Panels & Profiles Recent Developments 4.1 Recent Developments - Importance and How to Use This Section 4.1.1 Importance of These Developments 4.1.2 How to Use This Section

5. Profiles of Key Players

6. The Global Market for Cancer Gene Panels and Profiles

7. Global Cancer Gene Panels & Profiles Markets - By Type of Cancer 7.1 Comprehensive Panels & Profiles 7.2 Breast Cancer Gene Testing 7.3 Colorectal Cancer Gene Testing7.4 Gynecological Cancer Gene Testing 7.5 Blood Cancer Gene Testing 7.6 Prostate Cancer Gene Testing 7.7 Lung Cancer Gene Testing7.8 Other Cancer Gene Testing

8. Global Cancer Gene Testing Markets - Germline and Somatic 8.1 Global Market Somatic 7.3 Global Market Germline

9. Potential Market Opportunity Sizes 9.1 Potential Cancer Screening by Country: Lung, Breast & Colorectal 9.2 Potential Cancer Screening by Country: Prostate, Other Cancer & All Cancer 9.3 Potential Market Size - Cancer Diagnosis 9.4 Potential Market Size - Therapy Selection

Appendices

For more information about this report visit https://www.researchandmarkets.com/r/5bx3ai

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

More:
Global Genomic Cancer Panel and Profiling Markets Report 2021-2025: The Market is Moving Out of a Specialized Niche and Going Mainstream -...

Cancer Immunotherapy Market Estimated to be Worth USD 153.03 Billion by 2027 | CAGR of 10.1%: Emergen Research – PR Newswire UK

Posted on September 18, 2020 by Danzig

- The increasing prevalence of cancer and rising R&D activities in the cancer immunotherapy field is driving the demand for the market.

- Market Size USD 78.04 billion in 2019, Market Growth - CAGR of 10.1%, Market trends Growing health awareness and effectiveness of treatment

VANCOUVER, B.C, Sept. 17, 2020 /PRNewswire/ --The globalCancer Immunotherapy Marketis expected to reach USD 153.03 Billion by 2027, according to a new report by Emergen Research. The cancer immunotherapy market is growing at a substantial pace owing to the growing acceptance and inclination of the patients towards the newly invented advanced treatments over the conventional ones. In order to substantialize the severe and chronic diseases like cancer, every year, the cancer research centers invest a handful of the amount in their R&D, which fuels up the market growth by a large margin.

Key factors responsible for driving the growth of the cancer immunotherapy market include technological advancements in therapy, rising incidences of cancer, increasing R&D activities for the treatment of cancer, and the improving effectiveness of cancer immunotherapy for the treatment of a wide range of diseases, such as lung cancer, breast cancer, and skin cancer, among others. Factors that could significantly limit market growth is the high price of the slow and long-term procedure, expensive treatment and R&D, and stringent government regulations. Moreover, product approvals and high cost of treatment are expected to act as a restraining factor on the growth of the global market in the near future.

Request free sample of this research report at: https://www.emergenresearch.com/request-sample/63

Key Highlights From The Report

To get leading market solutions, visit the link below:https://www.emergenresearch.com/industry-report/cancer-immunotherapy-market

For the purpose of this report, Emergen Research has segmented the Global Cancer Immunotherapy Market on the basis of technology, application, end-use, and region:

Technology Outlook (Revenue, USD Billion; 2017-2027)

Application Outlook (Revenue, USD Billion; 2017-2027)

End-Use Outlook (Revenue, USD Billion; 2017-2027)

Regional Outlook (Revenue, USD Billion; 2017-2027)

Find more similar research insights by Emergen Research:

Hearing Aids MarketBy Type (Behind-the-ear- Hearing Aids, Receiver in-the-ear Hearing Aids, In-the-ear Hearing Aids, Canal Hearing Aids), By Hearing Loss, By Application (Adults, Pediatrics), By Distribution Channel, Forecasts to 2027

Continuous Glucose Monitoring System MarketBy Component (Insulin Pumps, Transmitters & Receivers, Sensors), By End Use (Hospitals, Homecare Settings, Others), and Regions Forecasts to 2027

Injectable Drug Delivery MarketBy Product Type (Formulations, Devices), By Therapeutic Application (Hormonal disorders, Autoimmune disorders, Oncology), By End-User (Homecare settings, Hospitals & Clinics), Forecasts to 2027

Molecular Diagnostics MarketBy Product (Reagents, Instruments), By Technology (DNA Sequencing and NGS, PCR, In Situ Hybridization), By Application (Oncology, Infectious Diseases), By End-User (Central Laboratories, Hospitals), Forecasts to 2027

Teleradiology Services MarketBy Imaging Technique (MRI, CT, X-Rays, Ultrasound, Mammography), By End-Users (Diagnostic Centers, Hospitals & Clinics), By Products and Services (Software, Hardware, Teleradiology services), Forecasts to 2027

Pharmacogenomics MarketBy Offering (Hardware, Software, Services), By Technology (Machine Learning, Natural Language Processing (NLP), Context-Aware Computing), By End-User Industry (Healthcare, Manufacturing, Agriculture, Automotive), and By Region, Forecasts to 2027

About Emergen Research

At Emergen Research, we believe in advancing with technology. We are a growing market research and strategy consulting company with an exhaustive knowledge base of cutting-edge and potentially market-disrupting technologies that are predicted to become more prevalent in the coming decade.

With market-leading insights and an in-depth understanding of leading and niche technologies, our solutions address the most pertinent questions for your business needs. A major technological shift has been witnessed towards creating a 'Circular Economy,' fuelled by factors, such as the increased adoption of bio-based materials, along with other methods for achieving carbon neutrality. We are conversant in technologies, viz., Artificial Intelligence (AI), Augmented Reality (AR), Virtual Reality (VR), Robotic Process Automation (RPA), Smart Manufacturing, Internet of Things (IoT), Big Data Analytics, Machine learning, Nanotechnology, Edge Computing, Blockchain Technology, Cloud Computing, Vehicle Electrification, Advanced Maintenance Analytics, and Predictive Maintenance, among other prevalent and emergent technologies.

Eric LeeCorporate Sales SpecialistEmergen Research | Web: https://www.emergenresearch.comE-mail: sales@emergenresearch.com

Read full Press Release at : https://www.emergenresearch.com/press-release/global-cancer-immunotherapy-market

Logo: https://mma.prnewswire.com/media/1252126/Emergen_Research_Logo.jpg

SOURCE Emergen Research

Pharmacogenomics Automotive Grease Market to Witness Growth Acceleration During 2020-2027 – Verdant News

Posted on September 22, 2020 by Danzig

The research study on Pharmacogenomics Market added byReportspediapresents an extensive analysis of current Pharmacogenomics Market size, drivers, trends, opportunities, challenges, as well as key market segments. In continuation of this data, the Pharmacogenomics Market report covers various marketing strategies followed by key players and distributors.

During the estimated period, the report also mentions the predictable CAGR of the global Pharmacogenomics Market. The report provides readers with accurate past statistics and predictions of the future. In order to get an in-depth overview of Global Pharmacogenomics Market is valued at USD XX million in 2020 and is predictable to reach USD XX million by the end of 2027, growing at a CAGR of XX% between 2020 and 2027.

Free Sample PDF Copy Here @:

https://www.reportspedia.com/report/life-sciences/2015-2027-global-pharmacogenomics-industry-market-research-report,-segment-by-player,-type,-application,-marketing-channel,-and-region/58762#request_sample

Top Key Players:

Bayer AGBecton, Dickinson and CompanyAffymetrix, Inc.F. Hoffmann-La Roche AGQIAGENAbbott Laboratories, Inc.Bio-Rad Laboratories, Inc.Thermo Fisher Scientific Inc.Illumina, Inc.AstraZeneca PLC

The report on Pharmacogenomics market is also provided, details of the company enclosed, SWOT analysis, and PESTEL, Porters five forces, and product life cycle. In the start, the report offers a basic introduction of the Pharmacogenomics industry containing its definition, applications and production technique. Then, the report illustrates the international key Pharmacogenomics industry players in detail.

Geographical Analysis of Pharmacogenomics Market:

Ask For [emailprotected]:

https://www.reportspedia.com/discount_inquiry/discount/58762

Pharmacogenomics Market Segmentation:

Pharmacogenomics Market Segmentation By Type:

DNA SequencingMicroarray, Polymerase Chain ReactionElectrophoresisMass SpectrometryOthers

Pharmacogenomics Market Segmentation By Application:

Drug DiscoveryTailored TreatmentOncologyPain ManagementOther Therapeutic Applications

Global Pharmacogenomics Market: Competitive Analysis

This section of the report identifies a variety of key manufacturers in the market. It helps the reader know the strategies and collaboration that players are focus on combat competition in the market. The wide-ranging report provides a major microscopic look at the market. The reader can discover the footprints of the manufacturers by knowing about the global revenue of manufacturers and sales by manufacturers during the forecast period of 2020 to 2027.

In this Pharmacogenomics market study, the following years are considered to project the market footprint:

History Year:2014 2018

Base Year:2018

Estimated Year:2019

Forecast Year:2020 2027

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected]:

Pharmacogenomics market research addresses the following queries:

Main points of the table of contents:

Chapter One: Report Overview

Chapter Two: Trends in Global Growth

Chapter Three: Market Share of Major Players

Chapter Four: Distribution by Type and Application

Chapter Five: United States

Chapter Six: Europe

Chapter Seven: China

Chapter Eight: Japan

Chapter Nine: Southeast Asia

Chapter Ten: India

Chapter Eleven: Central and South America

Chapter Twelve: Profiles of International Players

Chapter Thirteen: Market Forecast 2020-2027

Chapter Fourteen: Analyst Views / Findings

Get Full Table of [emailprotected]:

Thanks for reading this article; you can also get individual chapter wise section or region wise report versions like North America, Europe, and Asia.

Read the original here:
Pharmacogenomics Automotive Grease Market to Witness Growth Acceleration During 2020-2027 - Verdant News

Japan Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market and Forecast Analyzed in a New Research Report – The Daily Chronicle

Posted on September 23, 2020 by Danzig

Japan Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market 2018: Global Industry Insights by Global Players, Regional Segmentation, Growth, Applications, Major Drivers, Value and Foreseen till 2024

The report provides both quantitative and qualitative information of global Japan Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market for period of 2018 to 2025. As per the analysis provided in the report, the global market of Japan Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) is estimated to growth at a CAGR of _% during the forecast period 2018 to 2025 and is expected to rise to USD _ million/billion by the end of year 2025. In the year 2016, the global Japan Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market was valued at USD _ million/billion.

This research report based on Japan Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market and available with Market Study Report includes latest and upcoming industry trends in addition to the global spectrum of the Japan Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market that includes numerous regions. Likewise, the report also expands on intricate details pertaining to contributions by key players, demand and supply analysis as well as market share growth of the Japan Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) industry.

Request Sample Report @ https://www.marketresearchhub.com/enquiry.php?type=S&repid=2795996&source=atm

Japan Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Overview:

The Research projects that the Japan Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market size will grow from in 2018 to by 2024, at an estimated CAGR of XX%. The base year considered for the study is 2018, and the market size is projected from 2018 to 2024.

Leading manufacturers of Japan Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market:

segment by Type, the product can be split intoPCRIn-situ HybridizationImmunohistochemistrySequencingOthers

Market segment by Application, split intoOncologyNeurological DisordersCardiovascular DiseaseImmunological DisordersOthers

Based on regional and country-level analysis, the Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market has been segmented as follows:North AmericaUnited StatesCanadaEuropeGermanyFranceU.K.ItalyRussiaNordicRest of EuropeAsia-PacificChinaJapanSouth KoreaSoutheast AsiaIndiaAustraliaRest of Asia-PacificLatin AmericaMexicoBrazilMiddle East & AfricaTurkeySaudi ArabiaUAERest of Middle East & Africa

In the competitive analysis section of the report, leading as well as prominent players of the global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.The key players covered in this studyQiagen NVGE HealthcareAgilent TechnologiesF Hoffman La RocheFoundation MedicineThermo Fisher Scientific Inc.Leica Biosystems Nussloch GmBHPfizer

Make An EnquiryAbout This Report @ https://www.marketresearchhub.com/enquiry.php?type=E&repid=2795996&source=atm

Some important highlights from the report include:

You can Buy This Report from Here @ https://www.marketresearchhub.com/checkout?rep_id=2795996&licType=S&source=atm

The Questions Answered by Japan Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Report:

And Many More.

Scientists are working on vaccines that spread like a disease. What could possibly go wrong? – Bulletin of the Atomic Scientists

Posted on September 18, 2020 by Danzig

A worker conducts testing during the 2014 Ebola outbreak in Liberia. Credit: John Saindon/Centers for Disease Control and Prevention. CC BY 2.0.

Once a COVID-19 vaccine is approved for public use, officials around the world will face the monumental challenge of vaccinating billions of people, a logistical operation rife with thorny ethical questions. What if instead of orchestrating complicated and resource-intensive campaigns to vaccinate humans against emerging infectious diseases like COVID-19, we could instead stop the zoonotic diseases that sometimes leap from animals to people at their source? A small, but growing number of scientists think its possible to exploit the self-propagating properties of viruses and use them to spread immunity instead of disease. Can we beat viruses like SARS-CoV-2, the novel coronavirus, at their own game?

A virus that confers immunity throughout an animal population as it spreads in the wild could theoretically stop a zoonotic spillover event from happening, snuffing out the spark that could ignite the next pandemic. If the wild rats that host the deadly Lassa virus, for example, are vaccinated, the risks of a future outbreak among humans could be reduced. For at least 20 years, scientists have been experimenting with such self-spreading vaccines, work that continues to this day, and which has gained the attention of the US military.

For obvious reasons, public and scientific interest in vaccines is incredibly high, including in self-spreading vaccines, as they could be effective against zoonotic threats. The biologists Scott Nuismer and James Bull generated fresh media attention to self-spreading vaccines over the summer after publishing an article in the journal Nature Ecology & Evolution. But the subsequent reporting on the topic gives short shrift to the potentially significant downsides to releasing self-spreading vaccines into the environment.

Self-spreading vaccines could indeed entail serious risks, and the prospect of using them raises challenging questions.

Who decides, for instance, where and when a vaccine should be released? Once released, scientists will no longer be in control of the virus. It could mutate, as viruses naturally do. It may jump species. It will cross borders. There will be unexpected outcomes and unintended consequences. There always are.

While it may turn out to be technically feasible to fight emerging infectious diseases like COVID-19, AIDS, Ebola, and Zika with self-spreading viruses, and while the benefits may be significant, how does one weigh those benefits against what may be even greater risks?

How they work. Self-spreading vaccines are essentially genetically engineered viruses designed to move through populations in the same way as infectious diseases, but rather than causing disease, they confer protection. Built on the chassis of a benign virus, the vaccines have genetic material from a pathogen added to them that stimulates the creation of antibodies or white blood cells in infected hosts.

These vaccines could be particularly useful, some scientists say, for wildlife populations where direct vaccination is difficult due to issues like inaccessible habitats, poor infrastructure, high costs, or lack of resources. The idea, essentially, is to vaccinate a small proportion of a population through direct inoculation. These so-called founders will then passively spread the vaccine to other animals they encounter either by touch, sex, nursing, or breathing the same air. Gradually, these interactions could build up population-level immunity.

Self-spreading vaccines have some of their roots in efforts to reduce pest populations. Australian researchers described a virally spread immunocontraception, which hijacked the immune systems of infected animalsin this case a non-native mouse species in Australiaand prevented them from fertilizing offspring. The earliest self-spreading vaccine efforts targeted two highly lethal infectious diseases in the European rabbit population (myxoma virus and rabbit hemorrhagic disease virus). In 2001, Spanish researchers field-tested a vaccine in a wild rabbit population living on Isla del Aire, a small Spanish island just off Menorca. The vaccine spread to more than half the 300 rabbits on the island, and the trial was deemed a success.

In 2015, another team of researchers speculated on the development of a self-spreading vaccine for the Ebola virus that could be used on wild great apes like chimpanzees. Since then, scientists have come to see a wide array of animalsfrom wildlife such as bats, birds, and foxes to domesticated animals like dogs, pigs, and sheepas amenable to self-spreading vaccines.

So far, researchers have not developed experimental self-spreading vaccines for humans; there is no clear evidence that anybody is actively working on the technology. Nuismer and Bull argue, rather, that self-spreading vaccines present a revolutionary approach to control emerging infectious diseases before they even spill over from animals into the human population.

Zoonotic spillover is certainly a pressing problem; alongside SARS-CoV-2, HIV, Ebola virus, and the Zika virus, there are over a thousand other new viruses with zoonotic potential that have been detected in wild animals over the last decade. Prevention is better than a cure, Nuismer and Bull say in a New Scientist article. In their Nature Ecology & Evolution article, they claim they are poised to begin developing self-disseminating vaccines to target a wide range of human pathogens in animals.

Outside of an experiment, scientists would face massive technical and practical hurdles in identifying the most appropriate targets for intervention and ensuring immunity is maintained in the wildlife populations. Despite these substantial challenges, the potential security implications of self-spreading vaccines are even more serious.

The principal security concern is that of dual-use. In essence, this means that the same research that is used to develop self-spreading vaccines to prevent disease, could also be used to deliberately cause harm. You could, for instance, engineer triggers into a virus that cause immune system failures in infected people or animals, a bit like HIV does naturally. Or you could create triggers in a virus that cause a harmful autoimmune response, where the body starts attacking its own healthy cells and tissues.

The bioweapon question. While researchers may intend to make self-spreading vaccines, others could repurpose their science and develop biological weapons. Such a self-spreading weapon may prove uncontrollable and irreversible.

We dont have to dig very deep for a historical example of weaponized biology. As the apartheid-era South African biowarfare program shows, social, political, and scientific pressures can lead to the misuse of biological innovation.

Codenamed Project Coast, South Africas program was primarily focused on covert assassination weapons for use against individuals deemed a threat to the racist apartheid government. In addition to producing contraptions to inject poisons, Project Coast researchers developed techniques to lace sugar cubes with salmonella and cigarettes with Bacillus anthracis.

While there have been many biowarfare programs, including several that were far more elaborate and sophisticated, the South African program is particularly relevant in thinking through malicious uses of self-spreading vaccines. One of Project Coasts research projects aimed at developing a human anti-fertility vaccine.

The idea took hold during a time of widespread concern over worldwide population explosion. Schalk Van Rensburg, who oversaw fertility-related work at a Project Coast laboratory, told South Africas post-apartheid Truth and Reconciliation Commission, a forum for examining the sordid history of the era and laying the foundation for future peace and tolerance, that he thought the project was in line with the World Health Organizations attempts to curb rising global birth rates. He believed it could bring his lab international acclaim and funding. According to Van Rensburg, Wouter Basson, the director of the biowarfare program, said the military needed an anti-fertility vaccine so that female soldiers would not fall pregnant.

While some of the scientists involved in the project denied awareness of ulterior intentions or even that their fertility work was part of a military endeavor, Van Rensburg and Daniel Goosen, a lab director, told the Truth and Reconciliation Commission that the real intention behind the project was to selectively administer the contraceptive in secret to unwitting Black South African women.

In the end, the anti-fertility vaccine was not produced before Project Coast was officially closed down in 1995, 12 years after it was initiated. An early version was tested in baboons, but never in humans. South Africa isnt the only country to try and forcibly sterilize parts of its population. European countries, including Sweden and Switzerland, sterilized members of the Roma minority in the early half of the 20th century and some, like Slovakia, continued even beyond that. More recently, analysts have alleged that the Chinese government is sterilizing women in Xinjiang, a province with a large population of Uighur Muslims.

It doesnt take a massive leap of the imagination to see how the aims of South Africas anti-fertility vaccine project would have benefited from research into self-spreading vaccines, particularly if you combine it with current developments in pharmacogenomics, drug development, and personalized medicine. Taken together, these strands of research could help enable ultra-targeted biological warfare.

An expanding potential for abuse. The Biological Weapons Convention, the treaty that bans biological weapons, is nearly 50 years old. Negotiated and agreed to in the depths of the Cold War, the convention suffers from outdated modes of operation. There are also significant compliance assessment challenges. The convention certainly didnt stop South Africa from pursuing Project Coast in the early 1980s.

Self-spreading vaccine research is a small but growing field. At the moment, about 10 institutions are doing significant work in the area. These laboratories are primarily located in the United States, but some are in Europe and Australia, as well. As the field expands, so does the potential for abuse.

So far research has primarily been bankrolled by US government science and health funders like the National Science Foundation, the National Institutes of Health, and the Department of Health and Human Services. Private organizations like the Gates Foundation and academic institutions have also financed projects. Recently, the Defense Advanced Research Projects Agency (DARPA), sometimes thought of as the US militarys research and development wing, has gotten involved in the research. The University of California, Davis, for example, is working on a DARPA administered project called Prediction of Spillover Potential and Interventional En Masse Animal Vaccination to Prevent Emerging Pathogen Threats in Current and Future Zones of US Military Operation. According to a pamphlet, the project is creating the worlds first prototype of a self-disseminating vaccine designed to induce a high level of herd immunity (wildlife population level protection) against Lassa virus and Ebola.

Military investment in biological innovation for defensive or protective purposes is permissible under the Biological Weapons Convention, but it can still send the wrong signals. It could cause countries to doubt one anothers intentions and lead to tit-for-tat investment in potentially risky research, including in self-spreading vaccines. The result of research gone awry or biowarfare could be catastrophic for health and the environment.

At a time when the norm against chemical weapons is degrading, underscored most recently by the poisoning of Russian opposition leader Alexei Navalny with the nerve agent Novichoka crime for which many European officials blame Russiathe international community simply cant afford to have the same thing happen to the norm against the use of biological weapons. It would completely defy the spirit of the treaty if it seemed like states would even want to pursue high-risk dual use activities in biology.

Early, open, good-faith conversations about scientific aims and advances that cause particular dual-use concerns, as self-spreading vaccines do, are essential to exploring the broader stakes of certain technical trajectories. The University of California, Davis program is pursuing ways to incorporate an off switch to safely control the technology. And DARPA says any field experimentation related to the project would follow biosafety protocols. But these pledges wont suffice. Our ambition must be to make a collective decision about the technical pathways we are willing, or not willing, to take as a society.

The rest is here:
Scientists are working on vaccines that spread like a disease. What could possibly go wrong? - Bulletin of the Atomic Scientists

Medical Simulator Market 2020 Will Emerge Globally And Grow upto 13.8% of CAGR by 2023 – The Daily Chronicle

Posted on September 18, 2020 by Danzig

The Global Medical Simulator Market size is projected to reach USD XX Mn by 2023 from USD XX Mn in 2018, at a CAGR of 13.8% during the forecast period.

Global Medical Simulator Industry Research Report Provides Detailed Insight Covering all Important Parameters Including Development Trends, Challenges, Opportunities, Key Insights and Competitive Analysis of Medical Simulator Market.

View complete Report, https://www.alltheresearch.com/report/84/Medical-Simulator

With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Medical Simulator market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Medical Simulator market in terms of both revenue and volume.

Get Exclusive Sample Report on Medical Simulator Market is available at https://www.alltheresearch.com/sample-request/84

Impact of COVID-19: Medical Simulator Market report analyses the impact of Coronavirus (COVID-19) on the Medical Simulator industry. Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 180+ countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Medical Simulator market in 2020

COVID-19 can affect the global economy in 3 main ways: by directly affecting production and demand, by creating supply chain and market disturbance, and by its financial impact on firms and financial markets.

Download the Sample ToC to understand the CORONA Virus/COVID19 impact and be smart in redefining business strategies. https://www.alltheresearch.com/impactC19-request/84

Top 10 leading companies in the global Medical Simulator market are analyzed in the report along with their business overview, operations, financial analysis, SWOT profile and Medical Simulator products and services

Market Segmentation:

Top Players Listed in the Medical Simulator Market Report areVirtaMed, MS Tech, VRmagic, Simbionix, Gaumard Scientific, Ambu, Bioseb, CAE Healthcare, Creaplast, Medical Simulation Corporation (MSC), PerSys Medical, .

Based on type, The report split into 2D Simulator, 3D Simulator, .

Based on the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate for each application, including Hospitals, Diagnostic Laboratories, Research & Academic Laboratories, .

Get Special Discount Up To 50%, https://www.alltheresearch.com/speak-to-analyst/84

The study objectives of this report are:

FOR ALL YOUR RESEARCH NEEDS, REACH OUT TO US AT:Contact Name: Rohit B.Email:[emailprotected]Phone: 1-888-691-6870

See original here:
Medical Simulator Market 2020 Will Emerge Globally And Grow upto 13.8% of CAGR by 2023 - The Daily Chronicle

Global Pharmacogenomics Market Analysis, Drivers, Restraints, Opportunities, Threats, Trends, Applications, And Growth Forecast To 2028 – The Scarlet

Posted on September 3, 2020 by Danzig

Trusted Business Insights answers what are the scenarios for growth and recovery and whether there will be any lasting structural impact from the unfolding crisis for the Pharmacogenomics Market market.

Trusted Business Insights presents an updated and Latest Study on Pharmacogenomics Market Market 2019-2029. The report contains market predictions related to market size, revenue, production, CAGR, Consumption, gross margin, price, and other substantial factors. While emphasizing the key driving and restraining forces for this market, the report also offers a complete study of the future trends and developments of the market.The report further elaborates on the micro and macroeconomic aspects including the socio-political landscape that is anticipated to shape the demand of the Pharmacogenomics Market market during the forecast period (2019-2029).It also examines the role of the leading market players involved in the industry including their corporate overview, financial summary, and SWOT analysis.

Get Sample Copy of this Report @ Global Pharmacogenomics Market 2020 (Includes Business Impact of COVID-19)

Global Pharmacogenomics Market Analysis Trends, Applications, Analysis, Growth, and Forecast to 2028 is a recent report generated by Trusted Business Insights. The global pharmacogenomics market report has been segmented on the basis of technology, application, end user, and region.

Request Covid 19 Impact

Global Pharmacogenomics Market: Overview

Pharmacogenomics is a branch of genetics which is concerned with determining the response of an individual to particular drugs. It is a combination of pharmacology -the science of drugs and genomics which means the study of genes and their functions. Pharmacogenomics techniques are used for the development of effective and safe medications with specific genetic makeup.

Global Pharmacogenomics Market: Dynamics

Rising incidences of chronic diseases such as tuberculosis, cancer, HIV, and many others is a major factor anticipated to drive the growth of the global pharmacogenomics market over the forecast years. In addition, increasing number of geriatric population, higher adoption rate of pharmacogenomics procedure by the various healthcare professionals, and growing demand for personalized therapy are some of the other factors expected to drive revenue growth of the target market. Furthermore, higher health care expenditure and increasing incidences of lifestyle diseases are some among another factors expected to boost the demand for pharmacogenomics. However, high cost associated with test and lack of technical expertise and trained professional in developing and under developing countries are some of the major factors that may hamper the growth of target market to a significant extent.

Global Pharmacogenomics Market: Segment Analysis

Among the technology segments, polymerase chain reaction segment is expected to register the highest market share in terms of revenue as compared to other technologies. This is due to, increasing usage of PCR for in molecular biology for making many copies of a specific DNA segment and is very quick and accurate technique, resulting in higher adoption rate. Among the application segments, oncology is expected to anticipate highest market revenue share over the forecast period, owing to growing demand for the use of pharmacogenomics advent technologies in drug discovery and development for oncology treatment. Among the end user, hospitals and clinics are expected to account for significant share as compared to other end user segment. This can be due to, the presence of highly skilled and expects medical professionals with better infrastructure and advance technologies.

Global Pharmacogenomics Market: Trend

Major players are investing high amount for researcher activity in order to study the safety and efficiency of drugs. In addition, prominent manufacturers are collaborating with other research institute for carrying out clinical pharmacogenomics testing. Also, the government are funding companies that work for development of bioinformatics technology for precision medicine research applications. The above mentioned are among some of the key trends observed in the global pharmacogenomics market.

Global Pharmacogenomics Market: Regional Analysis

In 2019, the markets in North America is projected to a significant market share over the forecast period. This is primarily due to, presence of developed medical facilities and healthcare sector, increasing incidences of chronic diseases, and high patient awareness level in countries in the region. The market in the Asia Pacific is projected to register fastest growth rate over the forthcoming years. This can be primarily attributed to, increasing preference among patients for personalized treatment, increasing number of clinical trials as well as research and development activates in countries of Asia Pacific region.

Global Pharmacogenomics Market Segmentation:

Segmentation by technology:

Polymerase Chain ReactionMicroarraySequencingMass SpectrometryElectrophoresisOthers

Segmentation by application:

OncologyInfectious diseasesCardiovascular diseasesNeurological diseasesPsychiatryPain managementOthers

Segmentation by end user:

Hospitals and clinicsResearch institutionsAcademic institutes

Looking for more? Check out our repository for all available reports on Pharmacogenomics Market in related sectors.

Quick Read Table of Contents of this Report @ Global Pharmacogenomics Market 2020 (Includes Business Impact of COVID-19)

Trusted Business InsightsShelly ArnoldMedia & Marketing ExecutiveEmail Me For Any ClarificationsConnect on LinkedInClick to follow Trusted Business Insights LinkedIn for Market Data and Updates.US: +1 646 568 9797UK: +44 330 808 0580

The rest is here:
Global Pharmacogenomics Market Analysis, Drivers, Restraints, Opportunities, Threats, Trends, Applications, And Growth Forecast To 2028 - The Scarlet

Select Page ::